Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro

Sitravatinib, also called MGCD516 or MG-516, is a broad-spectrum tyrosine kinase inhibitor (TKI) under phase III clinical evaluation. Herein, we explored the activity of sitravatinib toward multidrug resistance (MDR) by emphasizing its inhibitory effect on ATP-binding cassette super-family G member...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Oncol
Autors principals: Yang, Yuqi, Ji, Ning, Teng, Qiu-Xu, Cai, Chao-Yun, Wang, Jing-Quan, Wu, Zhuo-Xun, Lei, Zi-Ning, Lusvarghi, Sabrina, Ambudkar, Suresh V., Chen, Zhe-Sheng
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7236772/
https://ncbi.nlm.nih.gov/pubmed/32477943
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00700
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars